HCW Biologics opened higher at $0.86, compared with its previous close of $0.86. In the last trading session, the stock traded between $0.76 and $0.89. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in HCW Biologics is now worth
$ 0.12
Resulting in a loss of
$ 99.88 (99.88%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.05 (-6.28%)
Day High
$0.89
Day Low
$0.76
Day Open
$0.86
Prev Close
$0.86
Volume
36,095
1W Return
-25.09%
1M Return
-47.04%
3M Return
-74.97%
6M Return
-56.44%
1Y Return
-95.25%
Fundamentals
Market Cap ($ Mn)
2
PE Ratio
-
PB Ratio
0.74
PEG Ratio
-
ROE
-
ROCE
-869.73%
EPS (TTM)
$-9.50
Investment Returns
1 Week
-25.09%
1 Month
-47.04%
3 Months
-74.97%
6 Months
-56.44%
9 Months
-86.43%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
6.5
Mar 26
0.1
Jun 26
Updates
6Nov
HCW Biologics abstract on HCW11-040 selected by SITC
HCW Biologics Inc.'s HCW11-040 data update selected as one of Top 150 Abstracts by SITC. Selection made from 1,200 submissions for scientific rigor and potential impact. Preclinical data shows HCW11-040 outperformed pembrolizumab in rejuvenating exhausted T cells. Novel fusion protein combines checkpoint blockade with cytokine-mediated immune activation. Presentation scheduled for November 7, 2026, at SITC Annual Meeting in Phoenix.
6 days ago
6Nov
HCW Biologics shows HCW11-018b converts cold tumors to hot at SITC
HCW Biologics presented preclinical data for HCW11-018b at the SITC 41st Annual Meeting. The lead candidate induces tertiary lymphoid structure formation in solid tumors. Data shows conversion of immunologically "cold" tumors to "hot" tumors via IL-15 and TGF-beta neutralization. IND application for first-in-human study planned for submission in first half of 2027. cGMP manufacturing has been initiated using a streamlined process similar to monoclonal antibodies.
6 days ago
3Oct
HCW Biologics files prospectus to resell 1.8 million warrant shares
HCW Biologics Inc. filed a prospectus with the SEC for share resale. Up to 1,807,228 shares underlying Armistice Capital warrants are covered. The filing facilitates potential public trading of exercised warrant shares.
